Mesa Laboratories MLAB Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $8.85M-29.9% | $14.37M+17.5% | $13.92M+17.3% | $11.49M-4.3% | $12.62M+3.5% | |
| Clinical Genomics | $12.18M+5.8% | $11.77M-7.1% | $11.14M-3.1% | $10.3M-9.7% | $11.51M+3.5% | |
| Revenue by Product | ||||||
| Service | $12.2M+11.3% | $11.05M+8.0% | $11.29M+9.6% | $11.2M+1.0% | $10.96M+4.9% | |
| Revenue by Geography | ||||||
| CN | $4.06M-19.5% | $5.65M-10.7% | $5.32M-28.1% | $5.43M-17.2% | $5.04M-20.6% | |
| Other | $29.61M+14.3% | $29.59M+13.6% | $26.12M+16.8% | $26.47M+6.9% | $25.89M+2.1% | |
| US | $30.06M-3.7% | $29.89M-1.9% | $29.3M+4.4% | $27.65M+2.9% | $31.2M+14.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
